Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cisplatin-E therapeutic implant

An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity.
Synonym:CDDP-e therapeutic implant
CDDP/epi
CDDP/epi gel
cisplatin-epinephrine
cisplatin/epinephrine gel
intradose MPI-5010
MP 5010 therapeutic implant
MP 5010 TI
US brand name:IntraDose
Abbreviation:CEG
Code name:MPI 5010
Search NCI's Drug Dictionary